Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$263 Mln
P/E Ratio
--
P/B Ratio
5.91
Industry P/E
--
Debt to Equity
0.52
ROE
-2.17 %
ROCE
-146 %
Div. Yield
0 %
Book Value
1.07
EPS
-1.55
CFO
$-331.09 Mln
EBITDA
$-372.52 Mln
Net Profit
$-486.80 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Abeona Therapeutics (ABEO)
| -4.31 | 4.10 | 1.33 | 68.14 | -5.07 | -38.68 | -24.99 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Abeona Therapeutics (ABEO)
| 11.08 | 62.66 | -63.76 | -78.34 | -51.99 | -54.20 | -54.76 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with... recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio. Read more
President, CEO & Director
Dr. Vishwas Seshadri M.B.A., Ph.D.
President, CEO & Director
Dr. Vishwas Seshadri M.B.A., Ph.D.
Headquarters
Cleveland, OH
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Abeona Therapeutics Inc (ABEO) stood at $ 109 Mln as on 31-Dec-24
The share price of Abeona Therapeutics Inc (ABEO) is $5.33 (NASDAQ) as of 25-Apr-2025 16:02 EDT. Abeona Therapeutics Inc (ABEO) has given a return of -5.07% in the last 3 years.
Abeona Therapeutics Inc (ABEO) has a market capitalisation of $ 263 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Abeona Therapeutics Inc (ABEO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Abeona Therapeutics Inc (ABEO) and enter the required number of quantities and click on buy to purchase the shares of Abeona Therapeutics Inc (ABEO).
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
The CEO & director of Dr. Vishwas Seshadri M.B.A., Ph.D.. is Abeona Therapeutics Inc (ABEO), and CFO & Sr. VP is Dr. Vishwas Seshadri M.B.A., Ph.D..
There is no promoter pledging in Abeona Therapeutics Inc (ABEO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Abeona Therapeutics Inc. (ABEO) | Ratios |
|---|---|
|
Return on equity(%)
|
-216.57
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Abeona Therapeutics Inc (ABEO) was $0 Mln.
$-0.06
(
